CA19-9 and CEA biosensors in pancreatic cancer
Document Type
Article
Publication Date
2-1-2024
Abstract
Cancer is a complex pathophysiological condition causing millions of deaths each year. Early diagnosis is essential especially for pancreatic cancer. Existing diagnostic tools rely on circulating biomarkers such as Carbohydrate Antigen 19-9 (CA19-9) and Carcinoembryonic Antigen (CEA). Unfortunately, these markers are nonspecific and may be increased in a variety of disorders. Accordingly, diagnosis of pancreatic cancer generally involves more invasive approaches such as biopsy as well as imaging studies. Recent advances in biosensor technology have allowed the development of precise diagnostic tools having enhanced analytical sensitivity and specificity. Herein we examine these advances in the detection of cancer in general and in pancreatic cancer specifically. Furthermore, we highlight novel technologies in the measurement of CA19-9 and CEA and explore their future application in the early detection of pancreatic cancer.
Keywords
Cancer biomarker, Biosensors, Clinical Diagnostics, Cancer detection, Point-of-care, Nanomaterials
Divisions
mechanical
Funders
Tenaga Nasional Berhad (TNB),Universiti Tenaga Nasional (UNITEN) through the BOLD Refresh post-doctoral fellowships,DCS-Universiti Tunku Abdul Rahman, Malaysia (J510050002-IC-6 BOLDRE-FRESH2025); (IPSR/RMC/UTARRF/2023-C1/P02)
Publication Title
Clinica Chimica Acta
Volume
554
Publisher
Elsevier
Publisher Location
RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS